Skip to main content

POSCO Holdings to Acquire 30% Stake in Australian Lithium Venture

Tipranks - Thu Nov 13, 2025

Meet Your ETF AI Analyst

POSCO ( (PKX) ) has shared an update.

On November 11, 2025, POSCO Holdings Inc. announced its decision to acquire a 30% stake in a new intermediate holding company to be formed by Mineral Resources Ltd. in Australia, aimed at operating in the lithium business. This strategic investment, valued at approximately 1.1 trillion KRW, is intended to strengthen POSCO’s position in the lithium market, thereby boosting its cost-competitiveness and expanding its footprint in the mining sector.

The most recent analyst rating on (PKX) stock is a Hold with a $53.00 price target. To see the full list of analyst forecasts on POSCO stock, see the PKX Stock Forecast page.

Spark’s Take on PKX Stock

According to Spark, TipRanks’ AI Analyst, PKX is a Neutral.

POSCO’s overall stock score reflects financial challenges with declining revenue and profitability, coupled with technical indicators showing mixed signals. The high P/E ratio suggests potential overvaluation, while the dividend yield offers limited compensation. The absence of earnings call and corporate events data means these factors were not considered.

To see Spark’s full report on PKX stock, click here.

More about POSCO

POSCO Holdings Inc. is a South Korean company operating in the steel industry, with a focus on expanding its operations into the lithium sector to enhance its cost-competitiveness.

Average Trading Volume: 134,940

Technical Sentiment Signal: Hold

Current Market Cap: $15.65B

Learn more about PKX stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.